- In the United States alone, close to one million people are living with MS, with a landmark study finding that figure was more than double what had previously been assumed.
- Treatments for progressive forms of MS remain especially elusive, and recent research notes that no currently approved therapy directly reverses the neurodegeneration that drives long-term disability.
- Quantum BioPharma’s Lucid-MS candidate is designed to inhibit demyelination directly by targeting an enzyme called peptidyl arginine deiminase 2.
Nearly three million people around the world wake up every day managing a disease that has no cure, and the number keeps climbing. That reality is what makes new approaches to multiple sclerosis worth paying attention to, and it is the space where Quantum BioPharma (NASDAQ: QNTM) is working to make a difference with its lead drug candidate: Lucid-MS.
Questions around this news
What is Lucid-MS designed to do?
The release describes Lucid-MS as a drug candidate intended to inhibit demyelination, the loss of myelin around nerve fibers. It says the candidate targets peptidyl arginine deiminase 2, an enzyme. The release does not provide clinical results or say whether the candidate has been shown to reverse disability.
Why are treatments for progressive multiple sclerosis difficult to develop?
The release says treatments for progressive forms of MS remain especially elusive. It also cites research noting that no currently approved therapy directly reverses the neurodegeneration associated with long-term disability. These points describe the treatment gap that new approaches, including candidates designed to affect demyelination, seek to address.
What does demyelination mean in multiple sclerosis?
Demyelination is damage to or loss of myelin, the insulating material surrounding nerve fibers. In multiple sclerosis, this can interfere with signals traveling through the brain and spinal cord. The effects vary, and demyelination is one part of a complex disease process.
Multiple sclerosis is a chronic disease of the central nervous system in which the immune system attacks myelin, the protective coating around nerve fibers in the brain and spinal cord. Global prevalence rose from about 2.3 million people in…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.IBN.ai
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM
Corporate Communications
IBN
Austin, Texas
www.IBN.ai
512.354.7000 Office
[email protected]
At a glance
- Company
- Quantum BioPharma
- Ticker
- NASDAQ: QNTM
- Announcement
- Product
Key figures
- People with MS in the United States
- close to one million
- People with MS worldwide
- Nearly three million
- Prior global prevalence figure mentioned
- about 2.3 million people
Products and programs
SEC filings
Earlier from Quantum BioPharma
- Quantum BioPharma (NASDAQ: QNTM) to Present at 3rd Annual ArcStone-Kingswood Growth Summit
- Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves
- Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2
- Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis
- Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Receives FDA Clearance to Advance Lucid-MS into Phase 2
